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OBJECTIVES:Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are painful con-
ditions that can have a substantial negative impact on patients’ lives. UK-specific
patient reported outcome (PRO) data on the debilitating impact of these conditions
is limited, however. A large-scale UK cross-sectional study, therefore, has recently
been conducted to address these limitations and further inform the scientific com-
munity. Findings from this study are summarised. METHODS: A combined total of
382 HZ and PHN patients over the age of 50 were recruited from 49 sites throughout
the UK. Participants were required to complete validated PRO measures of pain and
health-related quality of life (HRQoL), including the Zoster Brief Pain Inventory
(ZBPI) and the Medical Outcomes Study Short-Form 36 (SF-36). RESULTS: Pain was
a prominent symptom among patients, with more than 50% reporting experiencing
pain in the preceding 24 hours at levels typically considered to have a significant
impact on HRQoL (i.e. ZBPI worst pain 5). This was reflected in SF-36 domain and
summary scores that were significantly lower in HZ and PHN patients compared to
age-matched norms (p  0.05). When compared to normative samples, clinically
meaningful differences were observed among HZ and PHN samples across SF-36
domains assessing aspects of physical and mental well-being. In both groups,
HRQoL was inversely associated with levels of reported pain. CONCLUSIONS: Find-
ings indicate that the acute presentation of HZ and the development of PHN, the
most common complication of HZ and that can persist for several months, are
painful experiences that can have a significant impact on the physical and mental
wellbeing of HZ/PHN sufferers.
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OBJECTIVES: There is a growing debate regarding switching prescription (Rx) drugs
to over-the-counter (OTC) for chronic conditions as a viable option in the brand
lifecycle management and cost control. Further, patients are increasingly involved
in making informed treatment-related decisions. Using a novel patient registry, the
current study assessed satisfaction across ten widely used Rx and OTC medications
and evaluated the impact of Rx versus OTC status on treatment satisfaction for
these medications.METHODS:The registry recruited patients from multiple sourc-
es: physicians, pharmacies, and online referrals, to report ongoing medications on
www.MediGuard.org. A random sample of these patients was contacted to com-
plete the Treatment Satisfaction Questionnaire for Medication (TSQM) Version-I, a
14-item reliable and valid instrument to capture patients’ satisfaction with medi-
cation. The TSQM yields scores on four domains: effectiveness, side-effects, con-
venience, and global satisfaction. The study included patients on any of the ten Rx-
levothyroxine, metformin, atorvastatin, simvastatin, lisinopril, zolpidem, aripipra-
zole, esomeprazole, duloxetine, montelukast (n9,387) or OTC medications- ibu-
profen, acetaminophen, aspirin, multivitamin, cetrizine, omeprazole, omega,
naproxen, calcium carbonate, and loratadine (n7,226). Descriptive statistics and
regression analyses explored the differences in patients’ satisfaction across Rx
versus OTC medications. RESULTS: Overall, patients had mean (SD) age of 56.9
(12.4) years; 70.5% females and 73.8% White. The mean TSQM scores ranged from
61.4, 63.2 (acetaminophen, metformin) to 72.7, 76.4 (omeprazole, esomeprazole) on
effectiveness, from 93.0, 81.5 (cetirizine, aripiprazole) to 99.1, 97.6 (multivitamin,
esomeprazole) on side-effects, from 76.4, 78.1 (acetaminophen, metformin) to 88.2,
89.1 (loratadine, montelukast) on convenience and from 61.7, 61.1 (naproxen, met-
formin) to 73.8, 75.4 (cetirizine, esomeprazole) on global satisfaction. Compared to
Rx, OTC showed better side-effects profile and global satisfaction but had lower
effectiveness and convenience (p0.001) after adjusting for age, gender, race, self-
reported severity, and co-medications. CONCLUSIONS: The findings suggest that
differences in patients’ satisfaction profiles are associated with Rx versus OTC
medications.
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OBJECTIVES: We provided a comprehensive and detailed overview of the Spanish
burden of disease study for the year 2008. METHODS: We calculated disability-
adjusted life years (DALYs) at a country level using the methodology developed in
the Global Burden of Disease (GBD) study. DALYs were divided into years of life lost
because of premature mortality (YLLs) and years of life lived with disability (YLDs),
and are presented by sex and by age groups. Results were obtained using Spanish
specific-mortality data for the year 2008 and morbidity data estimated for Euro-A
region (European countries with very low mortality, including Spain) of the GBD
study. Data were analysed and prepared in GesMor and Epidat software. RESULTS:
In the year 2008, DALYs lost due to all diseases and injuries was estimated at 5.1
million (DALY rate per 1000 Spanish people of all ages and both sexes: 111.0). From
the total number of DALYs, 41.4% were due to premature mortality (YLLs) and
58.6% were due to disability (YLDs). Chronic non-communicable diseases ac-
counted for 89.2% of the total number of DALYs. The three main causes of DALYs
were neurological and mental disorders (29.9%), malignant neoplasms (15.8%), and
cardiovascular diseases (12.5%). The leading specific causes of DALYs were unipo-
lar depression (5.5%), ischaemic heart disease (5.5%), lung cancer (5.3%) and alcohol
abuse (4.7%) among males, and unipolar depression (11.7%), dementias (10.0%),
hearing loss (4.2%) and cerebrovascular disease (3.5%) among females.
CONCLUSIONS: Measuring DALYs specifically for Spain provides a systematic
analysis of health losses at a population level. The findings from this study suggest
that chronic non-communicable diseases would benefit from increased evidence-
based public health actions.
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OBJECTIVES:Calculate the country-level scores for the SF-36v2 subscales and com-
ponents for women with idiopathic menorrhagia treated with LNG-IUS; explore
between-country variability in HRQL experience of this condition; and evaluate the
treatment effect in different geographical settings. METHODS: Baseline and 12-
month data from a prospective, observational study of women with idiopathic
menorrhagia from 9 countries (Bulgaria, Croatia, India, Jordan, Romania, Russia,
Saudi Arabia, Serbia and Montenegro, and Turkey) were analyzed. Scores were
calculated for each of the eight domains and Physical and Mental component sum-
maries (PCS and MCS) of the SF-36v2. Hierarchical modeling was applied to account
for nested nature of observations within the countries. Frequentist mixed effects
regressions in STATA and Bayesian Markov Chain Monte Carlo simulation in Win-
BUGS were used to calculate country-level estimates, controlling for covariates.
RESULTS: Idiopathic menorrhagia negatively affects HRQL in different geographic
settings; in most countries baseline mean MCS scores are more than one standard
deviation (10 units) below the normative UK mean. Between-country variability
was confirmed in Bayesian and Frequentists analysis for baseline subscales (range:
36-86) and MCS and PCS (range: 35-51), indicating variation in experience with
menorrhagia. In general, 12-month estimates were much higher than those at
baseline, indicating substantial improvement in HRQL while on treatment, regard-
less of country. In addition, there was a consistent, positive relationship of haemo-
globin with the SF-36v2 subscales and the MCS. CONCLUSIONS:Women in 9 coun-
tries in the study are negatively affected by menorrhagia, though country-level
variation was seen. Improvement in HRQL while on treatment was consistent
across geographic settings. Exploration of potential country- or patient-level ef-
fects is recommended in future research.
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract related to benign prostatic hypertrophy (BPH) using medical treat-
ment under actual conditions of use. METHODS: A pragmatic cohort of patients
treated medically, was followed up for 6 months, using several validated question-
naires: IPSS, MSF4, and SF12. RESULTS:A total of 146 patients treated with Serenoa
Repens (hexanic extract) were evaluated, the mean age was 65.64 8.82 years, and
on average the diagnosis had been made 11 months previously. At 6 weeks, the IPSS
was significantly improved (p0.0001). This improvement in the IPSS score be-
tween 6 weeks (11.086.17) and inclusion (15.056.80) was 4 points. An improve-
ment was also observed at 3 months. At 6 months, the p-value was also significant
(p0.0001). The improvement in the IPSS score between 6 months (7.78423) and
inclusion (14.796.90) was 7 points.The physical dimension (50.187.39 at inclu-
sion) of the SF12 improved significantly (p0.0005) from the 6th week (52.466.10),
an improvement (2.51 points) that was confirmed at 6 months (52.076.54)
(p0.0052) in comparison with inclusion (49.567.53). The mental dimension
(49.187.63 at inclusion) of the SF12 improved significantly (p0.0069) at 6 month
(51.816.59). Improvement of 2.63 points. The MSF4 was unchanged.
CONCLUSIONS:We observed an improvement in the IPSS score from the 6th week;
this statistical improvement was confirmed by a significant clinical improvement
in the 6th month. This favourable progression is consistent with the improvement
observed for both dimensions of the SF12.
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OBJECTIVES: The aim of this study was to measure Health Related Quality of Life
among Pharmacy students at Medical University of Warsaw. METHODS: In March
2011, students from the Faculty of Pharmacy, Medical University of Warsaw were
surveyed with a set of HRQoL questionnaires. The survey was conducted in the
middle of the semester, when students have no exams, nor tests and was a part of
long-term Pharmacoeconomic Student Chapter’s project. Students self-completed
pen and pencil versions of questionnaires and didn’t receive any compensation.
They were asked to give information regarding sex, age, year of study, average
grade during the previous year of study and to complete final official Polish version
of EQ-5D-5L, followed by EQ-VAS, SF-36 v.1 and EQ-5D-3L. RESULTS: Three hun-
dred eighty three students were approached, 369 responded to EQ-5D-5L and SF-36
and were included in the final analysis. Missing data included: sex in 1 respondent,
age in 2 and EQ-VAS in 6 respondents. Concerning SF-36 dimensions, students
reported major problems in vitality 53.69  18.47 as opposed to physical function-
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ing 95.51 10.09. Mean rate of own health on EQ-VAS was 80.30 15.21 and mean
EQ-5D index, based on Polish TTO value set, was 0.94  0.07 (in the range from
-0.523 to 1). Students of 1st year reported lowest QoL independently of the measure
used: EQ-VAS 76.4 17.72 and EQ-index 0.92 0.07. CONCLUSIONS: Generic ques-
tionnaires used in the survey are sensitive enough for measuring quality of life in
young and relatively healthy population. Students of 1st year reported lowest qual-
ity of life with all questionnaires. The survey needs to be continued in next years.
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ANTECEDENTS AND ITS CONSEQUENCES
Budych K1, Helms TM1, Schultz C2
1German Foundation for the chronically Ill, Fuerth, Germany, 2Berlin Institute of Technology,
Berlin, Germany
OBJECTIVES:A growing body of evidence links effective physician-patient commu-
nication to desirable outcomes such as improved adherence to treatment and
higher satisfaction of both patient and physician. However, when it comes to rare
diseases, the patient is forced to become knowledgeable about his own disease
state and therapies. Our objective was to describe and specify the experiences of
patient-physician-interaction in rare diseases, to develop an empirically derived
typology of interaction patterns and to explore the challenges associated with each
of these patterns. METHODS: We designed a multi-case study as a series of semi
standardized interviews with patients suffering from rare diseases. Therefore we
extracted six different rare diseases: Amyotrophic lateral sclerosis, Marfan’s syn-
drome, Wilson’s disease, Epidermolysis bullosa, Duchenne muscular dystrophy
and Neurodegeneration with brain iron accumulation. A total of 120 interviews
were recorded, transcribed and analyzed thematically based on emerging codes.
RESULTS: As suggested, insufficient expertise of the health care providers proved
to be a major problem in the highly specialized treatment process of rare diseases.
Here, it is often the patient himself who becomes an expert to determine what kind
and how much service he needs. Thus, we could identify the patient-directed
interaction as a widely experienced communication pattern among patients with
rare diseases. Physician=s ability and willingness to accept the patient as an expert
emerged as a major determinant for patient satisfaction. CONCLUSIONS: People
with rare diseases often face challenges due to the low prevalence and the resulting
lack of knowledge among their providers. Our study showed the relevance of the
provider=s ability to acknowledge the active role of the patient as an informed,
involved and interactive partner in the treatment process. However, allowing the
patient to control therapy may require a change of mind-set with some long-
standing traditional roles in healthcare.
Individual’s Health – Health Care Use & Policy Studies
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MEDICINE PRESCRIBING PATTERNS IN HIV/AIDS AND NON-HIV/AIDS
CHILDREN: A COMPARITIVE STUDY IN THE PRIVATE HEALTH CARE SECTOR OF
SOUTH AFRICA
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OBJECTIVES: Although the prevalence of human immunodeficiency virus (HIV)
infection among children is reported to be high, little is known about antiretroviral
(ARVs) treatment patterns. This study aims to compare medicine prescribing pat-
terns of children with HIV/AIDS to those without HIV in the private health care
sector of South Africa. METHODS: A quantitative, retrospective drug utilisation
review was performed utilising medicine claims data of a pharmacy benefit man-
agement company. Data for a four-year period (January 1, 2005 to December 31,
2008) were analysed. The study population consisted of all children 12 years,
divided into those receiving ARV medications and a control group (not receiving
ARVs). Data were analysed using the SAS® Programme (9.1). RESULTS: A total of
0.2% of all children in 2005 (N 197 323) received ARVs versus 0.4% in 2008 (N 98
939). HIV/AIDS children received 7.39 4.69 prescriptions for ARVs per year during
2005 versus 9.72  4.49 in 2008. An average 3.05  0.65 ARVs were prescribed per
prescription in 2005 versus 3.19  0.58 in 2008. HIV/AIDS children received 11.51 
7.17 prescriptions for other medication (non-ARVs) per year during 2005 and 13.46
 7.14 during 2008 compared to 3.86  3.71 (d  0.8) prescriptions per year in 2005
and 4.36 4.05 (d 1.25) in 2008 for the control group. HIV/AIDS children received
mostly sulphonamides and combinations, followed by antitussives and expecto-
rants, penicillin and combination analgesics whereas the control group received
mostly penicillin followed by antitussives and expectorants, combination analge-
sics and analgesics/antipyretics. CONCLUSIONS: There was an increase in the
number of children with HIV/AIDS over the study period. These children received
significantly more prescriptions per year than the control group. Further research
is needed to investigate the future medicine treatment cost of HIV/AIDS children in
the South African private health care sector.
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ALPHA BLOCKERS, 5-ALPHA REDUCTASE INHIBITORS, PDE-5 INHIBITORS AND
ANTIMUSCARINIC MEDICATION USE IN US PATIENTS DIAGNOSED WITH
BENIGN PROSTATIC HYPERPLASIA, AND LOWER URINARY TRACT SYMPTOMS
WITH AND WITHOUT ERECTILE DYSFUNCTION
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OBJECTIVES: To evaluate the alpha blockers, 5-alpha reductase inhibitors, PDE-5
inhibitor and antimuscarinic medication use in US patients diagnosed with benign
prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS) and erectile dys-
function (ED). METHODS: Employing a retrospective study design on a large US
healthcare claims database (MarketScan), male patients aged 18with a diagnosis
for BPH, LUTS and/or ED between 1/1/07 and 12/31/09 were identified. Patients with
prostatectomy were excluded. Eligible patients had 24 months of continuous phar-
maceutical and medical benefit coverage. Chi-square and Wilcoxon tests were
used to make statistical comparisons between cohorts: BPH Only (BPH), ED Only
(ED), BPHED, BPHLUTS w/o ED and BPHLUTS w/ED. RESULTS: There were
308,844 patients that met inclusion criteria, and overall 33%, 15%, 19%, and 6% had
a prescription for alpha-adrenergic antagonist, 5-alpha-reductase inhibitor, phos-
phodiesterase-inhibitor, and antimuscarinic, respectively. Overall, 53% had medi-
cation use where 6% received combination therapy, 19% switched therapy and 36%
discontinued therapy. BPH patients had higher rates of combination medication
use (8% vs. 1%, p0.0001); switching (8% vs. 7%, p0.0017) and medical visits (17 vs.
14 mean visits, p0.0001) than ED patients. However, ED had higher rates of ther-
apy discontinuation (27% vs. 15%, p0.0001) than BPH and ED. In addition, BPHED
had higher switching (15% vs. 8%, p0.0001), discontinuation (24% vs. 15%,
p0.0001) and medical visits (19 vs. 17 mean visits/yr, p0.0001) than BPH. Further-
more, BPHLUTS w/ED had higher switching (24% vs. 18%, p 0.0001), discontin-
uation (27% vs. 22%, p0.0001) and incurred more medical visits (25 vs. 23 mean
visits/yr, p0.0001) than BPHLUTS w/o ED. CONCLUSIONS: BPH and BPHLUTS
patients with ED had higher switching and discontinuation rates than patients
without ED. Thus, patients with comorbid ED may require more extensive phar-
macologic management and monitoring, resulting in more medical visits than
patients without ED.
PIH54
ANALYSIS OF THE FORMULARY ENSURE CHILDREN’S HOSPITALS IN UKRAINE:
FIRST RESULTS
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OBJECTIVES: The Order of Ministry of Health (N 529 from July 22, 2009) was intro-
duced system of formulary medicines in Ukraine. In 2011 the third edition of the
Ukrainian State Formulary of medicines was made. However, the State formulary
for children in Ukraine has not been adopted. METHODS: We conducted a retro-
spective analysis of a local formulary for children, according to two divisions -
Children’s neonatology and intensive care for children in an Lviv medical hospital.
We used the method of ABC-analysis, the costs and rates of provision children’s
medicines for public funds and resources for parents. RESULTS: Established that
the local formulary of children’s health-care setting contains 443 medicines with
14 ATC -groups. The major share of exchanges takes four groups: A-20%; R-16%; J
-14%; N - 12%. Determined that the cost of treatment of pulmonary surfactant
preparations is 1175 euros for one child (at June 1, 2011, 1 Euro  11,40 UAH).
Provision of surfactant for infants for the budget is only about 28%, the rest is
funded by parents. In the Formulary 17 includes antibiotics, of which only 24%
provided by the budget, the rest - at the expense of patients.Innovational antibiot-
ics financed only by 2-4% of the requirement. In children’s hospitals 2.5% took
medication extemporal production, in particular vitamin powders, solutions, pow-
ders with folic acid, solution for rehydration, and others. CONCLUSIONS: Real data
of medicines in children’s hospitals do not meet the need. Necessary to create the
State formulary for children, costs to be financed from public funds. The method of
willingness to pay to determine the list of medicines that will pay parents.
PIH55
NECESSITY OF ADMISSIONS AND HOSPITALIZATIONS IN SELECTED TEACHING
UNIVERSITY AFFILIATED AND PRIVATE HOSPITALS OF SHIRAZ, IRAN IN 2007
Hatam N1, Askarian M2, Sarikhani Y3, Ghaem. H3
1Shiraz University of Medical Sciences(SUMS) -Shiraz - Iran, shiraz, Iran, 2Shiraz University of
Medical Sciences (SUMS, shiraz, Iran, 3Shiraz University of Medical Sciences (SUMS), shiraz, Iran
OBJECTIVES: The use of acute hospital beds is an issue of concern both to policy-
makers and practitioners. In most countries attempts to improve efficiency and
reduce costs in this sector. One of the most widely used instruments for assessing
inappropriate hospital use is Appropriateness Evaluation Protocol (AEP), which
consists of a set of standards based on objective criteria relating to the condition of
the patient or clinical services received. The aim of this study was to measure
inappropriateness of admission and inpatient stays in four major hospitals of
Shiraz, Iran. METHODS: One of the most widely used instruments for assessing
inappropriate hospital use is Appropriateness Evaluation Protocol (AEP), which
consists of a set of standards based on objective criteria relating to the condition of
the patient or clinical services received RESULTS: Results: The results showed that
22% of the total admissions in four hospitals were rated as inappropriate. Most and
least inappropriate admissions were found in both teaching university affiliated
hospitals. Our data show that a total of 29.6% (average 6.40%) of the hospital stays
in the sample were judged to be inappropriate. The result of Least Significant
Difference (LSD) Test showed a significant association between the mean days of
inappropriate stay and turn of admission in all hospitals. In all hospitals, a signif-
icant association was observed between inappropriateness of hospital stay, costs
and length of stay.CONCLUSIONS:Considering the findings of this study and other
studies in Iran and other countries, we can conclude that factors involving in
inappropriate admission of patients in the hospitals are mostly fixed and similar
factors. To solve this problem we can use some strategy such as: Improving the
performance of the referral system, using standard criteria for an appropriate eval-
uation protocol by the medical staff, Extending of outpatient diagnosis services for
reducing of inappropriate hospitalization.
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